Is J&J Going to Sell its Stroke Business?

Johnson & Johnson could be positioning itself to sell Cerenovus, its stroke business, according to a report from the Financial Times.

The report cites individuals familiar with the deal and said the acquisition could be as high as $1.5 billion. MD+DI reached out to J&J for comment about the rumored deal.